Breakfast Technical Briefing on Biotech Stocks -- Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, and Cytokinetics

Wednesday, November 22, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 22, 2017 /PRNewswire/ -- If you want a Stock Review on CALA, CLDX, CLVS, or CYTK then come over to

and sign up for your free customized report. Pre-market, dedicates attention to Calithera Biosciences Inc. (NASDAQ: CALA), Celldex Therapeutics Inc. (NASDAQ: CLDX), Clovis Oncology Inc. (NASDAQ: CLVS), and Cytokinetics Inc. (NASDAQ:
CYTK). According to a report on BayStreet on November 20th, 2017, the Biotech sector showed some life last week as it bounced from weekly lows and ended flat on the week. The iShares Nasdaq Biotechnology ETF is down 7.1% on the month but up 17.3% year-to-date. Daily Stock Tracker published free research reports on these stocks today at:

Calithera Biosciences

South San Francisco, California headquartered Calithera Biosciences Inc.'s shares gained 1.23%, closing Tuesday's trading session at $10.25. The stock recorded a trading volume of 1.01 million shares, which was above its three months average volume of 615,570 shares. The Company's shares have advanced skyrocketed 215.38% since the start of this year. The stock is trading 26.84% below its 200-day moving average. Additionally, shares of Calithera Biosciences, which focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the US, have a Relative Strength Index (RSI) of 30.88.

On November 02nd, 2017, Calithera Biosciences announced its financial results for the Q3 ended September 30th, 2017. Revenue was $7.3 million for Q3 2017; R&D expenses were $10.8 million; G&A expenses were $3.1 million; and net loss from operations was $6.1 million. Cash, cash equivalents, and investments totaled $196.5 million at September 30th, 2017. See our free and comprehensive research report on CALA at:

Celldex Therapeutics

On Tuesday, shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc .recorded a trading volume of 734,442 shares. The stock declined 1.40%, ending the day at $2.82. The Company's shares have advanced 1.08% in the past month and 21.55% in the previous three months. The stock is trading above its 50-day moving average by 1.93%. Furthermore, shares of Celldex Therapeutics, which focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics, have an RSI of 54.02.

On November 17th, 2017, Celldex Therapeutics announced that enrollment has opened in its open-label Phase-2 study of CDX-3379 in combination with cetuximab in patients with cetuximab-refractory, advanced head and neck squamous cell carcinoma (HNSCC). CDX-3379 is the Company's human monoclonal antibody that selectively binds and inhibits the activity of ErbB3, also known as HER3. ErbB3 may be an important receptor regulating cancer cell growth and survival as well as resistance to targeted therapies, and it is expressed in many cancers, including HNSCC. CLDX free research report is just a click away at:

Clovis Oncology

Boulder, Colorado headquartered Clovis Oncology Inc.'s stock finished theday4.24% lower at $61.17 with a total trading volume of 1.23 million shares. Shares of the Company have advanced 37.71% on an YTD basis. The stock is trading below its200-day moving average by 12.50%. Additionally, shares of Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally, have an RSI of 29.23.

On October 23rd, 2017, research firm Barclays initiated an 'Overweight' rating on the Company's stock, with a target price of $105 per share.

On November 01st, 2017, Clovis Oncology reported financial results for the quarter ended September 30th, 2017. Net loss for Q3 2017 was $60.7 million; R&D expenses totaled $38.9 million; and SG&A expenses totaled $35.0 million. The Company had $628.0 million in cash, cash equivalents, and available-for-sale securities as of September 30th, 2017. Sign up for your complimentary report on CLVS at:


Shares in South San Francisco, California headquartered Cytokinetics Inc. ended yesterday's session 25.68% lower at $8.25. The stock recorded a trading volume of 7.45 million shares, which was above its three months average volume of 485,690 shares. The Company's shares are trading 38.51% below their 200-day moving average. Moreover, shares of Cytokinetics, which focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining, have an RSI of 22.76.

On October 26th, 2017, Cytokinetics reported Q3 2017 results. Total revenues for Q3 2017 were $6.2 million; net loss was $32.4 million; total R&D expenses increased to $24.9 million; and G&A expenses increased to $9.7 million. As of September 30th, 2017, cash, cash equivalents, and investments totaled $308.2 million.

On November 21st, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $26 a share to $17 a share. Register for free on and download the latest research report on CYTK at:


Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


View original content:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store